Nitric oxide as a therapeutic agent.
The vasorelaxant property of inhaled nitric oxide is rapidly lost because it binds to hemoglobin. Its selective action in the pulmonary circulation and bronchial smooth muscle has the advantage of not decreasing systemic vascular resistance with resultant systemic hypotension. In the adult population, patients with ARDS, COLD, asthma, and increased pulmonary vascular resistance postoperatively are likely to benefit from inhaled nitric oxide, at least transiently. However, before inhaled nitric oxide can be recommended for routine use, further study of the potential adverse effects needs to be carried out.
Conti
C R
CR
D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy; D002908:Chronic Disease; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D009569:Nitric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011652:Pulmonary Circulation / Q000187:drug effects; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
D009569:Nitric Oxide